

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.

